What biomarker testing is recommended for early stage Multiple Myeloma

Biomarker Testing for Early-Stage Multiple Myeloma

When you're first diagnosed with multiple myeloma, your care team will order several important biomarker tests. These tests measure specific proteins and genetic markers in your blood and bone marrow that help doctors understand your disease and plan treatment. Let me walk you through what's typically recommended.

Blood-Based Biomarkers

M Protein and Immunoglobulin Testing

According to NCCN Guidelines, your doctors will measure:

• Serum protein electrophoresis (SPEP) - quantifies the amount of abnormal M protein (monoclonal protein) in your blood
• Serum immunofixation electrophoresis (SIFE) - identifies the specific type of M protein present (such as IgG kappa or IgA lambda)

These tests are crucial because the M protein level becomes your "tumor marker" - a measurable way to track whether treatment is working. As the NCCN Guidelines explain, "assessing changes in levels of various proteins, particularly the M protein, helps track disease progression and response to treatment."

Free Light Chain (FLC) Assay

This test measures free light chains (kappa and lambda) circulating in your blood. According to NCCN Guidelines, the serum FLC assay "yields high sensitivity while screening for MM and related plasma cell disorders" and is "helpful in prognostication." The FLC ratio is particularly important because it's required for documenting complete response to treatment.

Standard Chemistry Panel

Your doctors will also measure:

• Beta-2 microglobulin - a protein that reflects tumor cell characteristics and has prognostic significance
• Lactate dehydrogenase (LDH) - another marker of tumor burden
• Albumin - a protein that helps with risk stratification
• Calcium, creatinine, and kidney function tests - to assess organ damage from myeloma

Bone Marrow Genetic Testing (FISH Panel)

This is one of the most important tests for early-stage myeloma. According to NCCN Guidelines, a fluorescence in situ hybridization (FISH) panel should examine your plasma cells for specific chromosomal abnormalities:

• del(13) - deletion of chromosome 13
• del(17p13) - deletion of chromosome 17 (high-risk)
• t(4;14) - translocation between chromosomes 4 and 14 (high-risk)
• t(11;14) - translocation between chromosomes 11 and 14
• t(14;16) - translocation between chromosomes 14 and 16 (high-risk)
• t(14;20) - translocation between chromosomes 14 and 20 (high-risk)
• 1q21 gain/amplification - extra copies of chromosome 1 (associated with more aggressive disease)
• 1p deletion - loss of part of chromosome 1

Why This Matters: According to NCCN Guidelines, "the utility of this information is to determine biological subtype and for prognostic recommendations as well as candidacy for clinical trials." These genetic findings help your doctor predict how aggressive your myeloma might be and which treatments may work best.

TP53 Mutation Testing

NCCN Guidelines recommend next-generation sequencing (NGS) to assess for TP53 mutations. This is important because TP53 mutations are associated with higher-risk disease and may influence treatment decisions.

Flow Cytometry

Your bone marrow sample will be analyzed using multi-parameter flow cytometry to:

• Confirm the presence of abnormal plasma cells
• Quantify how many plasma cells are abnormal
• Identify the specific immunophenotype (protein markers) of your myeloma cells

Why These Tests Matter Together

Think of biomarker testing like creating a detailed profile of your specific myeloma. The M protein and free light chains give you a measurable way to track disease. The genetic tests (FISH and TP53) tell your doctors whether your myeloma is standard-risk or high-risk, which directly influences which treatments are recommended.

According to NCCN Guidelines, "risk stratification based on the chromosomal markers is being utilized for prognostic counseling, selection, and sequencing of therapy."

Questions to Ask Your Care Team

1. What is my specific M protein type, and what does that mean for my treatment options?
2. What were the results of my FISH panel, and do I have any high-risk chromosomal abnormalities?
3. What is my free light chain ratio, and how will you use this to monitor my treatment response?
4. Based on my biomarker results, what is my risk category (standard-risk vs. high-risk), and how does this affect my treatment plan?
5. Will you repeat these biomarker tests during treatment, and how often?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.